Special Issue "Human Biomonitoring in Health Risk Assessment: Current Practices and Recommendations for the Future"

A special issue of Toxics (ISSN 2305-6304). This special issue belongs to the section "Risk Assessment and Management".

Deadline for manuscript submissions: 31 March 2022.

Special Issue Editor

Dr. Christophe Rousselle
E-Mail Website
Guest Editor
The French Agency for Food, Environmental and Occupational Health & Safety (ANSES), 14 rue Pierre et Marie Curie, 94701 Maisons-Alfort CEDEX, France
Interests: chemical risk assessment in a regulatory context; endocrine disrupters; cosmetic products; reach, derivation of health-based guidance values (either for general population or for workers); biomonitoring data in risk assessments

Special Issue Information

Dear Colleagues,

In most health risk assessment (HRA) frameworks for chemicals, the default approach for exposure assessment is to estimate intake from different sources and different routes of exposure. These assessments are often made separately and then added when aggregate exposure scenarios are considered. Various uncertainties are associated with this approach and, depending on the scope of the assessment; it may over- or under-estimate the internal exposure. Human Biomonitoring (HBM) is an important and useful tool for assessing the internal exposure of humans resulting from aggregated exposure to chemicals. HBM can also provide a better estimate of exposure closed to the target organ. Inclusion of HBM data could improve HRA for the general population and for workers. Though there are still a number of obstacles that hinder the use of HBM data in a HRA, the growing availability of HBM data offers an opportunity for improving and refining RA.

This Special Issue intends to illustrate, using case studies, how HBM data can be used to better estimate internal exposure and resulting risks. Case studies either on exposure from the use of consumer products (cosmetic products, non-food products, etc.) or from exposures via food or water, in the general population or among workers, will contribute to better identifying the hurdles that prevent a broader use of HBM data in RA. New tools such as physiologically-based pharmacokinetic (PBPK) models, derivations of health-based guidance values, new approaches for integrating HBM with in vitro/in silico data, and adverse outcome pathways (AOP), by providing more accurate data on actual internal exposure, could improve HRA. The articles in this Special Issue are expected to give recommendations on the most suitable approaches for generating more reliable HRA.

Dr. Christophe Rousselle
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • human biomonitoring
  • risk assessment
  • internal exposure
  • aggregated exposure
  • guidance values
  • prioritization
  • mixtures

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Article
Relationship between Occupational Exposure to Airborne Nanoparticles, Nanoparticle Lung Burden and Lung Diseases
Toxics 2021, 9(9), 204; https://doi.org/10.3390/toxics9090204 (registering DOI) - 30 Aug 2021
Viewed by 201
Abstract
The biomonitoring of nanoparticles in patients’ broncho-alveolar lavages (BAL) could allow getting insights into the role of inhaled biopersistent nanoparticles in the etiology/development of some respiratory diseases. Our objective was to investigate the relationship between the biomonitoring of nanoparticles in BAL, interstitial lung [...] Read more.
The biomonitoring of nanoparticles in patients’ broncho-alveolar lavages (BAL) could allow getting insights into the role of inhaled biopersistent nanoparticles in the etiology/development of some respiratory diseases. Our objective was to investigate the relationship between the biomonitoring of nanoparticles in BAL, interstitial lung diseases and occupational exposure to these particles released unintentionally. We analyzed data from a cohort of 100 patients suffering from lung diseases (NanoPI clinical trial, ClinicalTrials.gov Identifier: NCT02549248) and observed that most of the patients showed a high probability of exposure to airborne unintentionally released nanoparticles (>50%), suggesting a potential role of inhaled nanoparticles in lung physiopathology. Depending on the respiratory disease, the amount of patients likely exposed to unintentionally released nanoparticles was variable (e.g., from 88% for idiopathic pulmonary fibrosis to 54% for sarcoidosis). These findings are consistent with the previously performed mineralogical analyses of BAL samples that suggested (i) a role of titanium nanoparticles in idiopathic pulmonary fibrosis and (ii) a contribution of silica submicron particles to sarcoidosis. Further investigations are necessary to draw firm conclusions but these first results strengthen the array of presumptions on the contribution of some inhaled particles (from nano to submicron size) to some idiopathic lung diseases. Full article
Show Figures

Graphical abstract

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

Title: USE of HBM data to support risk assessment of cosmetic products : example of BP-3
Authors: Christophe Rousselle
Affiliation: The French Agency for Food, Environmental and Occupational Health & Safety (ANSES), 14 rue Pierre et Marie Curie, 94701 Maisons-Alfort CEDEX, France
Abstract: The current approach to assess the safety of cosmetic ingredient by SCCS is to estimate an internal dose based on external scenario of exposure and skin penetration. In this paper we will explore and discuss how biomonitoring data could be used to improve this approach. We will illustrate with the example of the UV-filter benzophenone-3 as a case study developed in the European Joint Programme for human biomonitoring (HBM4EU).

Title: European Joint Programme for human biomonitoring (HBM4EU): Human Biomonitoring Guidance Values (HBM-GVs) derived for Bisphenol S and example of use of the HBM-GVs in risk assessments for some bisphenols.
Authors: Christophe Rousselle
Affiliation: The French Agency for Food, Environmental and Occupational Health & Safety (ANSES), 14 rue Pierre et Marie Curie, 94701 Maisons-Alfort CEDEX, France
Abstract: In this paper, the derivation of HBM-GVs for the general population and workers referring to BPS will be presented, based on points of departure selected from a rather large and recent dataset of animal regulatory studies or academic studies published in peer- reviewed journals and identified in Beausoleil et al. (submitted). Then we will highlight the usefulness of these HBM-GVs, when assessing the risk for bisphenol S and A

Back to TopTop